News

Published on 18 Oct 2021 on Insider Monkey via Yahoo Finance

Zogenix, Inc. (ZGNX): Hedge Funds Are Snapping Up


Article preview image

In this article we will take a look at whether hedge funds think Zogenix, Inc. (NASDAQ:ZGNX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically outperformed the market after adjusting for known risk factors.

Zogenix, Inc. (NASDAQ:ZGNX) has experienced an increase in enthusiasm from smart money recently. Zogenix, Inc. (NASDAQ:ZGNX) was in 28 hedge funds' portfolios at the end of the second quarter of 2021. The all time high for this statistic is 38. Our calculations also showed that ZGNX isn't among the 30 most popular stocks among hedge funds (click for Q2 rankings).

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds' small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 79 percentage points since March 2017 (see the details here). We have been able to outperform the passive index funds by tracking the moves of corporate insiders and hedge funds, and we believe small investors can benefit a lot from reading hedge fund investor letters and 13F filings.

NYSE.BMA price evolution
NASDAQ.AMPH price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Report Preview: What to...

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is set to release its Q3 2024 earnings on Nov 6, 2024...

GuruFocus.com · via Yahoo Finance 5 Nov 2024

Is Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) The Top Stock With Improving...

We recently made a list of Piper Sandler’s Top Technical Stock Picks: 20 Best Stocks. In this pie...

Insider Monkey · via Yahoo Finance 13 Oct 2024

Insider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals...

On June 10, 2024, Floyd Petersen, Director at Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), execut...

GuruFocus.com · via Yahoo Finance 28 May 2024

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript May 8, 2024 Amphas...

Insider Monkey via Yahoo Finance 9 May 2024

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Fundamentals Look Pretty Strong: Could The Market Be...

Amphastar Pharmaceuticals (NASDAQ:AMPH) has had a rough three months with its share price down 19...

Simply Wall St. via Yahoo Finance 3 May 2024

Amphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 Shares

William Peters, the Chief Financial Officer, Executive Vice President, and Treasurer of Amphastar...

GuruFocus.com via Yahoo Finance 9 Mar 2024

Amphastar Pharmaceuticals Inc Director Michael Zasloff Sells 12,500 Shares

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), a company specializing in the development, manufactu...

GuruFocus.com via Yahoo Finance 6 Mar 2024

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Call Transcript February 29, 2024 ...

Insider Monkey via Yahoo Finance 2 Mar 2024

Amphastar Pharmaceuticals Inc Reports Robust Revenue Growth and Strong Full-Year Performance

Net Revenues: $178.1 million for Q4 2023, a 32% increase year-over-year.GAAP Net Income: $36.2 mi...

GuruFocus.com via Yahoo Finance 28 Feb 2024

Institutional investors in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) lost 3.4% last week but...

Key Insights Given the large stake in the stock by institutions, Amphastar Pharmaceuticals' stock...

Simply Wall St. via Yahoo Finance 31 Jan 2024